![]() |
市场调查报告书
商品编码
1662652
2030 年高通量製程开发市场预测:按类型、製程、技术、应用、最终用户和地区进行的全球分析High Throughput Process Development Market Forecasts to 2030 - Global Analysis By Type, Process, Technology, Application, End User and By Geography |
根据 Stratistics MRC 的数据,全球高通量製程开发 (HTPD) 市场预计在 2024 年达到 111.5 亿美元,到 2030 年将达到 205.2 亿美元,预测期内的复合年增长率为 10.7%。高通量製程开发是指利用自动化系统、先进仪器和资料分析来快速测试和优化製药、生物技术、化学和材料科学等行业的各种製程。同时测试多种条件和变数的能力大大加快了研究和开发速度。 HTPD透过高效筛检大量资料、提高生产力并缩短新产品的上市时间来加速药物发现、化学製程优化和材料开发。
药物研发需求不断成长
HTPD技术使製药公司能够快速筛检大量化合物并优化潜在候选药物的发现。这满足了人们对更快、更有效的药物开发以解决复杂疾病和健康问题的日益增长的需求。这种加快程序降低了药物开发成本,同时大大缩短了上市时间。随着製药业面临越来越大的压力,需要为各种疾病提供新颖的治疗方法,使用 HTPD 系统进行高通量筛检和流程优化对于改善药物开发工作至关重要。
初期成本高
对于中小型企业来说,实施 HTPD 系统通常需要在机器人、先进的自动化设备和专用软体方面进行大量投资,而这些投资的成本都高得令人望而却步。此外,资料管理和与当前系统整合所需的基础设施进一步增加了成本。这些高昂的前期成本可能会使许多公司(尤其是新兴企业或资源较少的公司)难以进入市场。儘管 HTPD 预计将透过加快研究和开发提供长期成本效益,但初始成本可能会阻碍其采用,尤其是在以成本效率为首要任务或资源有限的公司。
化学和材料研究的复杂性日益增加
随着材料科学、能源研究和化学等领域变得越来越复杂,对有效、可扩展的检测技术的需求也日益增长。 HTPD 系统使研究人员能够同时快速测试和调整多种化学配方、反应条件和材料属性,从而大大缩短了开发时间。这种能力对于满足对聚合物、催化剂和奈米材料等先进材料日益增长的需求至关重要,因为这些材料需要大量的精度和实验。加速创新和满足市场预期需要透过自动化、高通量程序来管理这种复杂性的能力。
过度简化的风险
利用HTPD技术快速筛检大量化学物质和条件,加快了製程测试和最佳化,但存在遗漏复杂系统中重要细节的风险。由于速度快、自动化程度高,HTPD 可能会错过影响实验结果的罕见或细微变量,从而导致结论不完整或过度概括。在材料科学和药物研发等高度专业化的领域,这种过度简化可能会导致不准确或不充分的结果,最终导致代价高昂的失误并破坏整个开发过程的有效性。
COVID-19 疫情对高通量製程开发市场产生了变革性的影响。最初,研发活动面临严重干扰,导致计划延迟和进展缓慢。然而,随着对快速疫苗和药物开发的需求不断增加,HTPD 方法已成为人们关注的焦点,有助于加速筛检和测试过程。这项变化凸显了HTPD对于提高诊断能力和药物发现效率的重要性。因此,由于技术进步和对医药研发的投资增加,预计后疫情时代 HTPD 市场将持续成长。
预计实验室设备市场将在预测期内成长至最大
由于对药物研发的自动化和效率的需求不断增加,预计实验室设备部门将在预测期内占据最大的市场占有率。小型化和液体处理技术的进步使得同时测试许多样本成为可能,大大提高了吞吐量。此外,人工智慧和机器学习的融合将优化资料分析和实验过程,从而加快决策速度。降低成本和提高生产力的需求进一步推动了先进实验室设备的采用,这对于现代製药研究和开发倡议至关重要。
预计预测期内农业和食品业将以最高的复合年增长率成长。
预计预测期内农业和食品领域将实现最高成长率。物联网、人工智慧等自动化和数位技术的进步使得农业过程的精确监测和控製成为可能,从而提高了作物产量并减少了资源浪费。此外,消费者对品质和永续性的需求日益增长,促使农业生产者采用高通量方法来更快地开发创新食品。这种整合将增强农业部门在快速发展的市场中的整体弹性和竞争力。
在预测期内,亚太地区预计将占据最大的市场占有率,这得益于製药、生物技术和化学工业的快速成长。中国、印度和日本等国正在增加对研发的投资,推动对高效药物发现和流程优化工具的需求。此外,该地区对个人化医疗的日益关注,加上自动化和人工智慧技术的进步,正在推动采用 HTPD 系统来加速产品开发并加强各个领域的研发能力。
预计北美地区在预测期内将呈现最高的复合年增长率。这是因为该地区致力于加速药物发现、提高流程效率和推动个人化医疗,从而推动了对 HTPD 系统的需求。此外,北美主要製药公司、学术机构和合约研究组织 (CRO) 的存在正在推动高通量技术的创新和采用,使该地区成为 HTPD 解决方案的关键参与企业,从而实现更快、更具成本效益的开发过程。
According to Stratistics MRC, the Global High Throughput Process Development (HTPD) Market is accounted for $11.15 billion in 2024 and is expected to reach $20.52 billion by 2030 growing at a CAGR of 10.7% during the forecast period. High Throughput Process Development (HTPD) describes the use of automated systems, advanced instrumentation, and data analytics to rapidly test and optimize various processes in industries such as pharmaceuticals, biotechnology, chemicals, and materials science. It allows for the simultaneous testing of multiple conditions or variables, significantly speeding up research and development. HTPD accelerates drug discovery, chemical process optimization, and material development by efficiently screening large volumes of data, improving productivity, and reducing time-to-market for new products.
Increased demand for drug discovery and development
HTPD technologies allow pharmaceutical companies to screen large numbers of compounds quickly, optimizing the discovery of prospective drug candidates. This is in response to the growing need for faster and more efficient drug development to address complex diseases and health concerns. This expedited procedure lowers drug development expenses while significantly accelerating time to market. High-efficiency screenings and process optimization using HTPD systems are essential for improving drug development efforts as the pharmaceutical industry is under increasing pressure to provide novel therapies for a range of ailments.
High initial costs
For small to mid-sized businesses, the deployment of HTPD systems frequently necessitates a significant investment in robotics, sophisticated automation equipment, and specialist software, all of which might be prohibitively expensive. The entire cost is further increased by the infrastructure required for data management and integration with current systems. These hefty upfront expenses might make it difficult for many businesses to enter the market, particularly startups or those with tight resources. The initial price burden may hinder the adoption of HTPD, especially in businesses where cost-efficiency is a top priority or resources are limited, even though it promises long-term cost benefits by speeding up research and development.
Rising complexity in chemical and material research
The need for effective and scalable testing techniques is growing as sectors including materials science, energy research, and chemicals become more complex. HTPD systems drastically cut down on development time by enabling researchers to rapidly test and tune several chemical formulations, reaction conditions, and material attributes at once. This capacity is essential for meeting the rising demand for sophisticated materials that need a great deal of accuracy and experimentation, such as polymers, catalysts, and nanomaterials. Accelerating innovation and meeting market expectations require the ability to manage this complexity through automated, high-throughput procedures.
Risk of oversimplification
The rapid screening of huge amounts of chemicals and circumstances by HTPD technology speeds up process testing and optimization, but it also has the risk of missing important details in complicated systems. Because of its speed and automation, HTPD may miss rare or subtle variables that affect experiment results, resulting in conclusions that are either incomplete or too generalized. This oversimplification can lead to inaccurate or poor outcomes in highly specialized domains like materials science or drug discovery, which can eventually result in costly blunders and undermine the overall efficacy of the development process.
The COVID-19 pandemic had a transformative impact on the High Throughput Process Development (HTPD) market. Initially, research and development activities faced significant disruptions, delaying projects and slowing progress. However, as the need for rapid vaccine and drug development intensified, HTPD methodologies gained prominence, facilitating accelerated screening and testing processes. This shift highlighted the importance of HTPD in enhancing diagnostic capabilities and drug discovery efficiency. Consequently, the post-pandemic phase is expected to witness sustained growth in the HTPD market, driven by advancements in technology and increased pharmaceutical R&D investments.
The laboratory instruments segment is expected to be the largest during the forecast period
The laboratory instruments segment is expected to account for the largest market share during the forecast period, due to the increasing demand for automation and efficiency in drug discovery. Advances in miniaturization and liquid-handling technologies enable the simultaneous testing of numerous samples, significantly enhancing throughput. Additionally, the integration of artificial intelligence and machine learning optimizes data analysis and experimental processes, leading to faster decision-making. The need for cost reduction and improved productivity further propels the adoption of sophisticated laboratory instruments, making them essential for modern pharmaceutical research and development initiatives.
The agriculture & food segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the agriculture & food segment is predicted to witness the highest growth rate. Advances in automation and digital technologies, such as IoT and AI, enable precise monitoring and management of agricultural processes, leading to improved crop yields and reduced resource waste. Additionally, rising consumer demands for quality and sustainability push agricultural producers to adopt high-throughput methodologies for faster development of innovative food products. This integration enhances the overall resilience and competitiveness of the agricultural sector in a rapidly evolving market.
During the forecast period, the Asia Pacific region is expected to hold the largest market share fuelled by the rapid growth of the pharmaceutical, biotechnology, and chemical industries. Countries like China, India, and Japan are increasing their investments in research and development, fueling the demand for efficient drug discovery and process optimization tools. Additionally, the region's expanding focus on personalized medicine, coupled with advancements in automation and AI technologies, is driving the adoption of HTPD systems to accelerate product development and enhance research capabilities across diverse sectors.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the region's focus on accelerating drug discovery, improving process efficiency, and advancing personalized medicine is fueling demand for HTPD systems. Additionally, the presence of leading pharmaceutical companies, academic institutions, and contract research organizations (CROs) in North America fosters innovation and adoption of high-throughput technologies, making the region a key player in advancing HTPD solutions for faster, cost-effective development processes.
Key players in the market
Some of the key players in High Throughput Process Development (HTPD) market include Thermo Fisher Scientific Inc., Agilent Technologies, PerkinElmer Inc., Labcorp Drug Development, Biotage AB, Schrodinger, Inc., Waters Corporation, Eppendorf AG, Sartorius AG, GE Healthcare Life Sciences, Horiba Ltd., Hamilton Company, Qiagen N.V., Mettler-Toledo International Inc., and Tecan Group Ltd.
In April 2024, PerkinElmer launched the LabChip GXII Touch platform, designed to provide high-throughput protein analysis and characterization. The platform helps speed up the drug discovery process by efficiently screening protein-based samples.
In February 2024, Agilent Technologies introduced an upgraded version of its 1290 Infinity II LC system, enhancing capabilities for high-throughput analysis in process development, particularly for pharmaceutical and biotechnology applications.
In October 2023, Thermo Fisher Scientific launched the KINGFISHER Flex instrument to further enhance automation in sample preparation for high-throughput process development, enabling faster and more efficient workflows in biotech and pharmaceutical applications.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.